ArticleFrontiers in clinical diabetes and healthcare2023
Hyperinsulinemia: an early biomarker of metabolic dysfunction.
Article in Frontiers in clinical diabetes and healthcare, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 33 citations in OpenAlex.
- Effect of canagliflozin treatment on β-cell responsiveness in insulin-dysregulated horses: a 4-week, multi-arm, double-blind, randomized clinical trial.Journal of veterinary internal medicine · 2026Article
- Hyperinsulinaemia as a cause of obesity and cardiometabolic diseases.Nature reviews. Endocrinology · 2026Review
- Birthweight phenotype genotype mismatch in cardiometabolic programming.Communications medicine · 2026Article
- Personalized Combination of a Ketogenic Diet and Low-Dose Semaglutide for Cardiometabolic Health: A Retrospective Case Series.Journal of personalized medicine · 2026Article
- Article
- Prevalence of hyperinsulinemia and its association with measures of adiposity and body composition in 16-25-year-old adolescents and young adults in Mumbai.BMC endocrine disorders · 2026Article
- Determinants of HbA1c Variability Across Clinical Subgroups: When the Same Value Does Not Reflect the Same Biological Risk.Medicina (Kaunas, Lithuania) · 2026Observational
- Article
- Diabetes and cancer: therapeutic implications.Cardio-oncology (London, England) · 2026Review
- Article
- Insulin Resistance at the Crossroads of Metabolic Inflammation, Cardiovascular Disease, Organ Failure and Cancer.Biomolecules · 2025Review
- Triglyceride Accumulation in Adipocytes Modulated by Insulin Dynamics.International journal of molecular sciences · 2025Article
- The Association of Insulin Sensitivity, Secretion, and Clearance With Subclinical Atherosclerosis in Middle-Aged Adults Without Diabetes: A Cross-Sectional Analysis of the SCAPIS Cohort.Journal of diabetes · 2025Article
- Multisystem Symptoms in Myotonic Dystrophy Type 1: A Management and Therapeutic Perspective.International journal of molecular sciences · 2025Review
- Associations between physical activity, brain health, cognitive function, and circulating GPLD1 in healthy older (65-85 years) individuals.GeroScience · 2025Observational
- Ryanodine Receptors in Islet Cell Function: Calcium Signaling, Hormone Secretion, and Diabetes.Cells · 2025Review
- Diet-enhanced LRG1 expression promotes insulin hypersecretion and ER stress in pancreatic beta cells.Diabetologia · 2025Article
- Dietary and lifestyle indices for hyperinsulinemia and odds of MAFLD in overweight and obese children and adolescents.Scientific reports · 2025Article
- Prevalence and determinants of insulin resistance in recovered COVID-19 and uninfected residents of two regional capitals in Ghana: An observational study.PLOS global public health · 2025Article
- Deciphering the role of classical oestrogen receptor in insulin resistance and type 2 diabetes mellitus: From molecular mechanism to clinical evidence.BioImpacts : BI · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hyperinsulinemia in the absence of impaired glucose tolerance and normal HbA1c is considered indicative of pre-diabetes. Very few Indian studies have focused on hyperinsulinemia particularly in young adults. The present study aimed to determine whether hyperinsulinemia may be present despite HbA1c being normal. Methods: This was a cross-sectional study conducted on adolescents and young adults aged 16-25 years living in Mumbai, India. The participants attended various academic institutions and were those who underwent screening as the first step of a clinical trial for studying the efficacy of almond intake in prediabetes. Results: Among this young population (n=1313), 4.2% (n=55) of the participants were found to be prediabetic (ADA criteria) and 19.7% of them had HbA1c levels between 5.7%-6.4%. However, almost, 30.5% had hyperinsulinemia inspite of normal blood glucose levels and normal HbA1c. Among those with HbA1c<5.7 (n=533), 10.5% (n=56) participants had fasting insulin>15 mIU/L and a higher percentage (39.4%, n=260) had stimulated insulin above 80 mIU/L. These participants had higher mean anthropometric markers than those with normal fasting and/or stimulated insulin. Conclusion: Hyperinsulinaemia in the absence of impaired glucose tolerance and normal HbA1c may provide a much earlier indicator of detection for risk of metabolic disease and progression to metabolic syndrome and diabetes mellitus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.